Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study.
The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed
by a multiple ascending dose (MAD) part (Part B).
The decision to escalate between dose levels and proceed to Part B will be based upon review
of blinded available safety data by a Safety Review Committee.